Consensus $69.47M. The company said, "Sight Sciences now projects revenue for the full year 2022 to range from $70 million to $72 million, which represents growth of approximately 43% to 47% compared to 2021. This compares to the prior expectation for full year 2022 revenue to range from $68 million to $72 million."
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SGHT:
- Sight Sciences Reports Third Quarter 2022 Financial Results
- Sight Sciences to Report Third Quarter 2022 Financial Results on November 10, 2022
- Sight Sciences Announces Publication of Data Showcasing Superior Symptoms Improvements with the TearCare® System Compared to LipiFlow* in Patients with Advanced Dry Eye Disease (DED)
- Sight Sciences to Feature Interactive Panel Discussions of Real-World Use of the OMNI Surgical System as a Standalone (Non-Combination Cataract) Glaucoma Treatment at American Academy of Ophthalmology Annual Meeting
- Sight Sciences OMNI® Surgical System to Be Featured in Multiple Presentations at the 2022 European Society of Cataract and Refractive Surgery Annual Meeting